These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26991522)

  • 1. Glucagon-like peptide-1 and vitamin D: anti-inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells.
    Einbinder Y; Ohana M; Benchetrit S; Zehavi T; Nacasch N; Bernheim J; Zitman-Gal T
    Diabetes Metab Res Rev; 2016 Nov; 32(8):805-815. PubMed ID: 26991522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells.
    Zitman-Gal T; Einbinder Y; Ohana M; Katzav A; Kartawy A; Benchetrit S
    J Diabetes; 2019 Aug; 11(8):656-664. PubMed ID: 30575282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D receptor activation in a diabetic-like environment: potential role in the activity of the endothelial pro-inflammatory and thioredoxin pathways.
    Zitman-Gal T; Golan E; Green J; Bernheim J; Benchetrit S
    J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):1-7. PubMed ID: 22531461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis.
    Kushima H; Mori Y; Koshibu M; Hiromura M; Kohashi K; Terasaki M; Fukui T; Hirano T
    Cardiovasc Diabetol; 2017 Oct; 16(1):122. PubMed ID: 28969637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation.
    Dai Y; Mehta JL; Chen M
    Cardiovasc Drugs Ther; 2013 Oct; 27(5):371-80. PubMed ID: 23657563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide.
    Lampropoulou E; Lymperopoulou A; Charonis A
    Metabolism; 2016 Jan; 65(1):7-15. PubMed ID: 26683792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation.
    Zhang H; Chu Y; Zheng H; Wang J; Song B; Sun Y
    Aging (Albany NY); 2020 Nov; 13(1):525-536. PubMed ID: 33298623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.
    Shiraki A; Oyama J; Komoda H; Asaka M; Komatsu A; Sakuma M; Kodama K; Sakamoto Y; Kotooka N; Hirase T; Node K
    Atherosclerosis; 2012 Apr; 221(2):375-82. PubMed ID: 22284365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
    Sourris KC; Ding Y; Maxwell SS; Al-Sharea A; Kantharidis P; Mohan M; Rosado CJ; Penfold SA; Haase C; Xu Y; Forbes JM; Crawford S; Ramm G; Harcourt BE; Jandeleit-Dahm K; Advani A; Murphy AJ; Timmermann DB; Karihaloo A; Knudsen LB; El-Osta A; Drucker DJ; Cooper ME; Coughlan MT
    Kidney Int; 2024 Jan; 105(1):132-149. PubMed ID: 38069998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
    Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
    Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis.
    Kapodistria K; Tsilibary EP; Kotsopoulou E; Moustardas P; Kitsiou P
    J Cell Mol Med; 2018 Jun; 22(6):2970-2980. PubMed ID: 29524296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The protection of islet β-cells in db/db mice by combination pioglitazone and glucagon like peptide-1 treatment].
    Song LL; Xiao JZ; Yang WY; Zhang M; Liu BB; Pan L
    Zhonghua Nei Ke Za Zhi; 2011 Sep; 50(9):781-4. PubMed ID: 22176969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.
    Mansur SA; Mieczkowska A; Bouvard B; Flatt PR; Chappard D; Irwin N; Mabilleau G
    J Cell Physiol; 2015 Dec; 230(12):3009-18. PubMed ID: 26016732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress.
    Schisano B; Harte AL; Lois K; Saravanan P; Al-Daghri N; Al-Attas O; Knudsen LB; McTernan PG; Ceriello A; Tripathi G
    Regul Pept; 2012 Feb; 174(1-3):46-52. PubMed ID: 22120833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.
    Fujita H; Morii T; Fujishima H; Sato T; Shimizu T; Hosoba M; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
    Kidney Int; 2014 Mar; 85(3):579-89. PubMed ID: 24152968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.
    Hendarto H; Inoguchi T; Maeda Y; Ikeda N; Zheng J; Takei R; Yokomizo H; Hirata E; Sonoda N; Takayanagi R
    Metabolism; 2012 Oct; 61(10):1422-34. PubMed ID: 22554832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP/PKA mediated down-regulation of MLC phosphorylation.
    Tang ST; Tang HQ; Su H; Wang Y; Zhou Q; Zhang Q; Wang Y; Zhu HQ
    Biomed Pharmacother; 2019 May; 113():108667. PubMed ID: 30852419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
    Yamada S; Tanabe J; Ogura Y; Nagai Y; Sugaya T; Ohata K; Natsuki Y; Ichikawa D; Watanabe S; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
    Clin Exp Nephrol; 2021 Apr; 25(4):365-375. PubMed ID: 33409761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
    Li P; Tang Z; Wang L; Feng B
    Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice.
    Ma DL; Chen FQ; Xu WJ; Yue WZ; Yuan G; Yang Y
    J Neurochem; 2015 Oct; 135(2):301-8. PubMed ID: 26183127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.